How to use the speech recognition tool?



A Long-term Follow-up Study to Evaluate the Safety and efficacy of Retinal Gene Therapy in Subjects with choroideremia treated previously with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) in an Antecedent Study.

Type: Observational

Status of the trial: Active, Recruiting

Orphan Drug Recognition: Yes


  • Opening Date: 2017-01-01
  • Closing Date: 2027-03-27


Inclusion: Subjects are willing and able to give informed consent for participation in the study, and have received a sub-retinal injection of AAV2-REP1 for CHM in an antecedent study.

Exclusion: There are no exclusion criteria for this study.

More information

Children: No

Adults: Yes

Funder Type: industry

HCP: Other investigators

Within ERN-EYE members

Principal investigators

Other investigators


  • Retinal Rare Eye Diseases (WG1)


* indicates required

This ERN is supported by: